Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 Combined With Adebrelimab in Advanced Pancreatic Ductal Adenocarcinoma
NCT06427239Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Fudan University. Started Jun 2024; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06427239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427239.